+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Next-Generation Sequencing Informatics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • ID: 4760201
  • Report
  • February 2021
  • Region: Global
  • 120 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Agilent Technologies Inc.
  • Dnanexus Inc.
  • F. Hoffmann-La Roche Ltd
  • llumina Inc.
  • Partek Incorporated
  • PerkinElmer, Inc
  • MORE
The Next Generation Sequencing Informatics Market is valued at approximately USD 2,250 million in 2020 and is expected to witness a revenue of USD 5,750 million in 2026, with a CAGR of 19% over the forecast period (2021-2026).

The NGS Informatics market is expected to peak during the current COVID-19 pandemic. The Next Generation Sequencing is considered to be a valuable tool in the characterization and identification of the SARS-CoV2 virus. Though qPCR is extensively used in the detection and quantification of coronavirus in the pandemic, the major disadvantage is that qPCR is unable to decipher accurate changes or mutations in the viral genome. Thus, NDS technologies play a vital role in studying the mutations in the viral genome and their impact on human health. According to a research article published in Clinical OMICS, 2020, approximately 84,000 viral genomic sequences of the coronavirus have been uploaded to Global Initiative to Share All Influenza Data (GISAID) by August 2020, and the analysis of 4,641 genomes revelated that the virus continues to mutate as it spreads, with one or two base changes per month. In this context, NGS plays a vital role in studying the evolving process of the SARS-CoV2 virus and the subsequent impact of these changes on the global population and environmental health, along with tracking the transmission of the virus globally. Thus, given the aforementioned factors, the COVID-19 pandemic is expected to impact the studied market significantly.

Additionally, the major factors driving the growth of the next-generation sequencing informatics market studied are the increasing clinical applications of next-generation sequencing (NGS), technological advancements in NGS informatics tools, growing preference toward personalized medicines and early disease diagnosis, along with the increasing demand for NGS services and investments by key players. Applications include whole-genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses. There are various technological advancements in the field of medicine that are growing at a rapid pace and has led to the development of personalized medicine. There are a huge number of applications of next-generation sequencing in personalized medicine. Thus, the development of personalized medicine has opened many avenues for the application of NGS, which could accelerate the market growth. When compared to Sanger sequencing, NGS has emerged as the dominant genomics technology because of its cost effectiveness and has been in use in a wide range of functional genomics applications, from sequencing a group of candidate genes, all coding regions (known as exome sequencing) to the entire human genome. Thus, the wide range of applications of NGS technology in turn increases the demand for NGS informatics, which in turn aids in the growth of studied market over the forecast period.

However, the unavailability of skilled professionals for the analysis and data interpretations of NGS data, along with the lack of knowledge of new informatics tools among medical professionals, is likely to limit the growth of the market studied. Additionally, the high cost involved in the maintenance and security of informatics tools is likely to contribute to the limitation.

Key Market Trends

Genetic Screening Segment, by Application, is Expected to Experience the Fastest Growth in the Market

In genetic screening, the NGS technology is highly useful in identifying the monogenic diseases with locus heterogeneity, such as blindness, deafness, movement disorders, mitochondrial disease, hereditary cancers, etc. It generates a large amount of sequencing data in a massively parallel manner, in order to provide a differential diagnosis for the patient. There are several companies in the market that provide NGS services for a range of genetic disorders and screening of DNA, RNA, and specialized samples. There is a high scope of technological improvement in the application of NGS, in genetic testing. According to the research article published in Trends in Genetics, 2019, the next-generation sequencing technologies, have remarkable potential in the genetic testing and diagnosis of rare genetic disorders. NGS technologies are expected to be highly useful in clinical settings to identify specific causal mutations in the DNA sequence. According to Rare Disease day, rare diseases are estimated to affect nearly 3.5% - 5.9% of the worldwide population in 2020 with over 300 million people living with one or more of over 6,000 identified rare diseases around the world. Thus, the high incidence of rare diseases surges the demand for genetic screening and NGS technologies have promising results in genetic screening. Additionally, NGS technologies have been extensively harnessed in oncology screening and the high incidence of cancers worldwide is expected to drive the studied market.

Additionally, the growing NGS platform launches drive the market growth. For instance, in Aug 2020, Quest Diagnostics launched the Automated NGS engine to aid in faster and cost-effective genetic screening. The increasing NGS product launches raise the demand for subsequent bioinformatics and thus, the aforementioned factors are expected to drive the growth of the studied market over the forecast period.

North America Dominates the Market and Expected to do Similar Over the Forecast Period

North America is expected to dominate the overall market throughout the forecast period. The presence of high per capita healthcare expenditure, coupled with high patient awareness levels and high prevalence of target diseases, is contributing to the growth of the market studied in the region. In the North American region, the United States holds the largest market share. According to the GLOBOCON 2020, the new cancer cases diagnosed were 2,281,658 in the United States in 2020, with 612,390 deaths. Among all cancers, breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), Prostate(209,512), and colon(101,809) new cancer cases in 2020 in the United States. The increasing incidence of chronic diseases is expected to drive the need for next-generation sequencing panels, which in turn surges the studied market growth. Also, various government bodies, like NHGRI (National Human Genome Research Institute, United States), have been supporting research related to human genome sequencing, while funding research related to the genome's structure, function, and role in health and disease. Moreover, these organizations support studies on ethical, legal, and social implications (ELSI) of genome research.

Also, the high concentration of major players in the region, followed by high product approval and launches is expected to be the major factor for the growth of the studied market in the region. For instance, in July 2019, Abbott launched a laboratory information management system, STARLIMS Life Sciences Solution 11.1, to help manage complex sample and testing workflows in pre-clinical, clinical research, biorepository, animal health, molecular, specialty diagnostics, and academic research. Thus, given the aforementioned factors, the NGS informatics market is expected to boost over the forecast period in North America.

Competitive Landscape

The next-generation sequencing informatics market is consolidated and consists of few major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of target diseases, few other smaller players are expected to enter the market. Some of the major players of the market are Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Intrexon Bioinformatics Germany GmbH, and Illumina Inc., among others. Most of these companies are involved in strategic alliances such as acquisitions, research, and development activities, along with new product launches to expand the product portfolio globally. For instance, in Jan 2020, Illumina Inc entered into a 15-year non-exclusive collaboration agreement with Roche and the launch of TruSight Software Suite v1.0 to accelerate adoption of genomics.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies Inc.
  • Dnanexus Inc.
  • F. Hoffmann-La Roche Ltd
  • llumina Inc.
  • Partek Incorporated
  • PerkinElmer, Inc
  • MORE
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Clinical Applications of NGS
4.2.2 Technological Advancements in NGS Informatics Tools
4.2.3 Growing Preference toward Personalized Medicines and Early Disease Diagnosis
4.2.4 Increasing Demand for NGS Services and Rising Investment by Key Players
4.3 Market Restraints
4.3.1 Lack of Skilled Technicians for NGS Informatics Services
4.3.2 Challenges Associated with Data Storage and Integration
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Products and Services
5.1.1 NGS Informatics Services
5.1.2 Data Analysis and Management Tool
5.1.2.1 Storage and Computing Tool
5.1.2.2 Laboratory Information Management System (LIMS)
5.1.2.3 Data Interpretation and Reporting Tools
5.1.3 Primary and Secondary Data Analysis Tools
5.2 By Application
5.2.1 Drug Discovery
5.2.2 Genetic Screening
5.2.3 Precision Medicine
5.2.4 Other Applications
5.3 By End User
5.3.1 Hospitals and Clinics
5.3.2 Academics and Research Institutes
5.3.3 Pharmaceuticals Companies
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Dnanexus Inc.
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Intrexon Bioinformatics Germany GmbH (Genomatix AG)
6.1.5 llumina Inc.
6.1.6 Fabric Genomics Inc. (Omicia Inc.)
6.1.7 Partek Incorporated
6.1.8 Qiagen NV
6.1.9 Sapio Sciences
6.1.10 Thermo Fischer Scientific Inc.
6.1.11 DNASTAR Inc.
6.1.12 PerkinElmer, Inc
6.1.13 BIOVIA(Dassault Systemes)
6.1.14 IBM Corporation
6.1.15 GENEWIZ, Inc.
6.1.16 Eagle Genomics Ltd
6.1.17 Real Time Genomics Inc.
6.1.18 SoftGenetics, LLC
6.1.19 PierianDx, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Agilent Technologies Inc.
  • Dnanexus Inc.
  • F. Hoffmann-La Roche Ltd
  • Intrexon Bioinformatics Germany GmbH (Genomatix AG)
  • llumina Inc.
  • Fabric Genomics Inc. (Omicia Inc.)
  • Partek Incorporated
  • Qiagen NV
  • Sapio Sciences
  • Thermo Fischer Scientific Inc.
  • PerkinElmer, Inc
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll